The new generation device includes optimized instrumentation designed to improve patient safety and surgeon ease of use. The device also maximizes central cavity space for autograft packing to facilitate fusion through the implant.
Here are five quick facts about the Valeo II:
• It’s made of a micro composite silicon nitride biomaterial to enhance osteointegration.
• ValeoII contains anti-infective properties.
• The device is semi-radiolucent with clearly visible boundaries in X-rays.
• There are no artifacts produced under MRI or CT scans.
• The device is for use in skeletally mature patients.
“This second generation TL device, in tandem with our anterior, posterior and oblique lumbar second generation silicon nitride interbody devices, greatly strengthens our ability to capture additional share with the $1.4 billion spinal interbody fusion device market,” says Amedica President and CEO Eric Olson.
More articles on orthopedic devices:
Aurora Spine launches new TiNano-coated lumbar interbody cages
Ortho Kinematics partner with Medtronic—5 things to know
5 spine device companies ready for prime time
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
